1-4 of 4
Ruizhi Zhao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L)

Free
Amer Zeidan, Yuexi Wang, Rebekah Yu, Aliza Matusevich, Ruizhi Zhao
Journal: Blood
Blood (2025) 146 (Supplement 1): 8176.
https://doi.org/10.1182/blood-2025-8176
Published: 2025
Journal Articles

Time burden of treatment with parenteral hypomethylating agents in combination with venetoclax among patients with newly diagnosed Acute Myeloid Leukemia

Free
Amer Zeidan, Ruizhi Zhao, Arthur Voegel, Dina Christensen, Maryia Zhdanava, Anabelle Tardif-Samson, Claire Vanden Eynde, Harold Keer, Dominic Pilon
Journal: Blood
Blood (2025) 146 (Supplement 1): 6990.
https://doi.org/10.1182/blood-2025-6990
Published: 2025
Journal Articles

Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

Free
Amer M. Zeidan, Ruizhi Zhao, Dudith Pierre-Victor, Yuexi Wang, Jon Tepsick, Ziyu Lan, Tehseen Salimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 5189.
https://doi.org/10.1182/blood-2024-205495
Published: 2024
Journal Articles

Real-World Experience with Anemia and Iron Overload Therapies in Myelodysplastic Syndromes (MDS): Treatment Sequence, Duration, and Patient Compliance

Free
Krystal Huey, Ruizhi Zhao, Tao Gu, Trong Kim Le, Shalon Jones, Luciana Bueno, Derek Tang
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-136684
Published: 2020